KR20200144579A - 피리미딘 유도체의 약학 염 및 장애의 치료 방법 - Google Patents

피리미딘 유도체의 약학 염 및 장애의 치료 방법 Download PDF

Info

Publication number
KR20200144579A
KR20200144579A KR1020207035669A KR20207035669A KR20200144579A KR 20200144579 A KR20200144579 A KR 20200144579A KR 1020207035669 A KR1020207035669 A KR 1020207035669A KR 20207035669 A KR20207035669 A KR 20207035669A KR 20200144579 A KR20200144579 A KR 20200144579A
Authority
KR
South Korea
Prior art keywords
compound
methyl
salt
pharmaceutically acceptable
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207035669A
Other languages
English (en)
Korean (ko)
Inventor
랜던 제이. 두라크
마리안 랭스턴
프라딥 쿠마르 샤르마
타이 히엡 응우옌
슈앙리안 리
샤오광 장
Original Assignee
어리어드 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어리어드 파마슈티칼스, 인코포레이티드 filed Critical 어리어드 파마슈티칼스, 인코포레이티드
Publication of KR20200144579A publication Critical patent/KR20200144579A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020207035669A 2018-05-14 2019-05-13 피리미딘 유도체의 약학 염 및 장애의 치료 방법 Ceased KR20200144579A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862671166P 2018-05-14 2018-05-14
US201862671182P 2018-05-14 2018-05-14
US62/671,166 2018-05-14
US62/671,182 2018-05-14
PCT/US2019/032002 WO2019222093A1 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Publications (1)

Publication Number Publication Date
KR20200144579A true KR20200144579A (ko) 2020-12-29

Family

ID=68540756

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035669A Ceased KR20200144579A (ko) 2018-05-14 2019-05-13 피리미딘 유도체의 약학 염 및 장애의 치료 방법

Country Status (11)

Country Link
US (1) US12084431B2 (https=)
EP (2) EP3793993A4 (https=)
JP (2) JP2021523208A (https=)
KR (1) KR20200144579A (https=)
CN (1) CN112313223A (https=)
AU (1) AU2019269372A1 (https=)
BR (1) BR112020023107A2 (https=)
CA (1) CA3099737A1 (https=)
MX (1) MX2020012063A (https=)
TW (1) TWI831780B (https=)
WO (1) WO2019222093A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3943491T (pt) 2019-03-19 2025-07-28 Voronoi Inc Derivado de heteroarilo, método para a produção do mesmo e composição farmacêutica que compreende o mesmo como componente eficaz
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US20220340547A1 (en) * 2019-05-22 2022-10-27 Shanghi Hansoh Biosoh Biomedical Co., Ltd. Indole derivative-containing inhibitor, preparation method therefor and application thereof
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023277172A1 (en) 2021-06-30 2023-01-05 Takeda Pharmaceutical Company Limited Process for preparing pharmaceutical salts of pyrimidine derivatives
EP4367116A4 (en) * 2021-07-07 2025-04-30 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibition, and compositions and methods therefor
JP7734995B2 (ja) * 2021-08-06 2025-09-08 上海和誉生物医薬科技有限公司 ピリミジンまたはピリジン誘導体およびその製造方法ならびに薬学上の応用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029958C (zh) 1986-03-31 1995-10-11 联合碳化农产化学品公司 丙二酸衍生物阻滞植物生长的用途
JP2749578B2 (ja) 1986-03-31 1998-05-13 ローヌープーラン・ネーデルランド・ベー・ベー 相乗的植物成長調節剤組成物
EP0261226A1 (en) 1986-03-31 1988-03-30 Rhone Poulenc Nederland B.V. Use of malonic acid derivative compounds for increasing crop yield
EP1100788B1 (en) * 1998-07-30 2005-11-09 Wyeth Substituted quinazoline derivatives
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7019017B2 (en) 2002-05-14 2006-03-28 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
EP1778648A2 (en) 2004-08-19 2007-05-02 ICOS Corporation Compounds useful for inhibiting chk1
KR20080057296A (ko) 2005-10-21 2008-06-24 머크 앤드 캄파니 인코포레이티드 칼륨 채널 억제제
PT1948180E (pt) 2005-11-11 2013-05-10 Boehringer Ingelheim Int Tratamento de combinação de cancro compreendendo inibidores de egfr/her2
TW200826843A (en) 2006-09-13 2008-07-01 Sumitomo Chemical Co Thiadiazole compound and use thereof
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2010093808A1 (en) 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
CN104684906B (zh) 2012-05-11 2017-06-09 艾伯维公司 Nampt抑制剂
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2015039613A1 (zh) 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
KR101879422B1 (ko) 2013-09-18 2018-07-17 베이징 한미 파마슈티컬 컴퍼니 리미티드 Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
EP3119763A1 (en) 2014-03-18 2017-01-25 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
EP3778584A1 (en) * 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
WO2016054987A1 (zh) 2014-10-11 2016-04-14 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
CN106995437A (zh) * 2016-01-22 2017-08-01 齐鲁制药有限公司 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
US11026937B2 (en) * 2016-09-12 2021-06-08 Padlock Therapeutics, Inc. Heteroaryl inhibitors of PAD4

Also Published As

Publication number Publication date
CA3099737A1 (en) 2019-11-21
EP3793993A1 (en) 2021-03-24
TWI831780B (zh) 2024-02-11
JP2024051160A (ja) 2024-04-10
TW202015687A (zh) 2020-05-01
WO2019222093A1 (en) 2019-11-21
AU2019269372A1 (en) 2020-11-26
US12084431B2 (en) 2024-09-10
CN112313223A (zh) 2021-02-02
EP3793993A4 (en) 2022-01-05
BR112020023107A2 (pt) 2021-02-02
JP2021523208A (ja) 2021-09-02
MX2020012063A (es) 2021-04-13
EP4234547A3 (en) 2023-11-01
EP4234547A2 (en) 2023-08-30
US20210309640A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US12084431B2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
US20210017163A1 (en) Hydrochloride salt form for ezh2 inhibition
JP2018024708A (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
WO2018210296A1 (zh) 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
JP2022521491A (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
JP2022548689A (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
HK40096550A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
JP2024529533A (ja) Ｅｒｂｂおよびｂｔｋ阻害剤の新規な医薬塩および多形形態
HK40046158A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
HK40109783A (en) Hydrochloride salt form for ezh2 inhibition
KR20210155806A (ko) Pi3k 저해제의 결정다형 및 이의 제조방법
NZ718201B2 (en) Hydrochloride salt form for ezh2 inhibition
HK1227873B (en) Hydrochloride salt form for ezh2 inhibition
HK1227873A1 (en) Hydrochloride salt form for ezh2 inhibition

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000